New research suggests that people who come off popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end traditional lifestyle regimens.
Findings released in a prominent health publication shows that while obese individuals often shed substantial amounts of their total mass while undergoing treatment, the mass comes back at an estimated rate of nearly a kilo each month once they quit.
"People purchasing these treatments need to be informed of the risk of rapid rebound weight gain when the treatment concludes," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to pre-treatment weight within about one and a half years.
Analyzing Approaches
The research, which reviewed dozens of studies involving thousands of patients, contrasted the outcomes of the injectable medications with conventional dieting.
Scientists emphasize that people who lose weight through diet and exercise typically have a more gradual weight regain—around 0.1 kg a month—after stopping.
Explaining the Rapid Regain
Experts propose the mode of action of the injections explains the heightened weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement means appetite is uncontrolled, making overeating a significant risk."
A Chronic Issue?
Health authorities suggest the injections for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Professionals say that, due to the likelihood of weight regain, the therapy is often long-term.
This perspective is echoed by pharmaceutical companies, who say that the results "underscore the chronic character of obesity," comparing it to managing diseases like diabetes.
User Experiences
Individuals who have come off the jabs explain a intense resurgence of appetite.
"It was like something activating and I was suddenly extremely hungry," said an individual.
This difficulty is exacerbated if patients have not established permanent lifestyle or habit modifications during treatment.
Significant Use
Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Use is greater among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Finally, clinicians emphasize that while the jabs are powerful tools for shedding pounds, they are not a standalone solution and long-term success relies on ongoing lifestyle management.
